A Bausch + Lomb drug from a 2025 acquisition missed main and secondary objectives of a Section 2 take a look at in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming to succeed the place Allergan, now an AbbVie subsidiary, fell quick within the clinic.
The publish Glaucoma Drug Fails Trial, However Bausch + Lomb Sees Alternative in One other Eye Illness appeared first on MedCity Information.
